Skip to main content

bcl-2 inhibitor bgb-21447

Generic: Bcl-2 Inhibitor BGB-21447

bcl-2 inhibitor bgb-21447: 2 clinical trials tracked.

bcl-2 inhibitor bgb-21447 evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bcl-2 inhibitor bgb-21447, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Metastatic Breast Cancer
Clinical Trials (2)

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

NCT06756932·Phase 1·ONC
Recruiting

Primary endpoint: Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen120 targetStarted 2025-02Completion 2027-0714 sites · Australia, China, United StatesBeOne Medicines

A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies

NCT05828589·Phase 1·ONC
Terminated

Primary endpoint: Part 1: Number of participants with dose limiting toxicities (DLTs)

InterventionalRandomizedopen51 enrolledStarted 2023-06Completion 2026-0628 sites · Australia, China, New Zealand, United StatesBeOne Medicines